X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs ALEMBIC PHARMA - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE ALEMBIC PHARMA CADILA HEALTHCARE/
ALEMBIC PHARMA
 
P/E (TTM) x 19.5 27.3 71.4% View Chart
P/BV x 4.6 5.5 83.9% View Chart
Dividend Yield % 0.9 0.6 143.7%  

Financials

 CADILA HEALTHCARE   ALEMBIC PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
ALEMBIC PHARMA
Mar-18
CADILA HEALTHCARE/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs558645 86.5%   
Low Rs362470 76.9%   
Sales per share (Unadj.) Rs116.3166.1 70.0%  
Earnings per share (Unadj.) Rs17.921.9 81.6%  
Cash flow per share (Unadj.) Rs23.127.5 84.1%  
Dividends per share (Unadj.) Rs3.504.00 87.5%  
Dividend yield (eoy) %0.80.7 106.1%  
Book value per share (Unadj.) Rs85.4117.8 72.5%  
Shares outstanding (eoy) m1,023.74188.52 543.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.03.4 117.8%   
Avg P/E ratio x25.725.5 101.1%  
P/CF ratio (eoy) x19.920.3 98.0%  
Price / Book Value ratio x5.44.7 113.7%  
Dividend payout %19.618.3 107.2%   
Avg Mkt Cap Rs m470,664105,090 447.9%   
No. of employees `00011.8NA-   
Total wages/salary Rs m18,5456,228 297.8%   
Avg. sales/employee Rs Th10,072.7NM-  
Avg. wages/employee Rs Th1,569.1NM-  
Avg. net profit/employee Rs Th1,547.7NM-  
INCOME DATA
Net Sales Rs m119,04931,308 380.2%  
Other income Rs m1,13270 1,610.2%   
Total revenues Rs m120,18131,378 383.0%   
Gross profit Rs m28,4756,431 442.8%  
Depreciation Rs m5,3881,055 510.9%   
Interest Rs m91134 2,679.4%   
Profit before tax Rs m23,3085,413 430.6%   
Minority Interest Rs m6280-   
Prior Period Items Rs m0-81 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6441,204 469.0%   
Profit after tax Rs m18,2924,128 443.1%  
Gross profit margin %23.920.5 116.4%  
Effective tax rate %24.222.2 108.9%   
Net profit margin %15.413.2 116.5%  
BALANCE SHEET DATA
Current assets Rs m82,00518,247 449.4%   
Current liabilities Rs m60,72011,235 540.5%   
Net working cap to sales %17.922.4 79.8%  
Current ratio x1.41.6 83.2%  
Inventory Days Days7386 85.5%  
Debtors Days Days9861 160.2%  
Net fixed assets Rs m83,70320,035 417.8%   
Share capital Rs m1,024377 271.6%   
"Free" reserves Rs m86,42121,824 396.0%   
Net worth Rs m87,44522,201 393.9%   
Long term debt Rs m25,5515,000 511.0%   
Total assets Rs m180,65339,411 458.4%  
Interest coverage x26.6160.2 16.6%   
Debt to equity ratio x0.30.2 129.7%  
Sales to assets ratio x0.70.8 83.0%   
Return on assets %10.610.6 100.6%  
Return on equity %20.918.6 112.5%  
Return on capital %22.019.7 111.5%  
Exports to sales %046.4 0.0%   
Imports to sales %010.5 0.0%   
Exports (fob) Rs mNA14,535 0.0%   
Imports (cif) Rs mNA3,288 0.0%   
Fx inflow Rs m42,68314,722 289.9%   
Fx outflow Rs m11,2427,026 160.0%   
Net fx Rs m31,4417,696 408.5%   
CASH FLOW
From Operations Rs m9,1933,124 294.3%  
From Investments Rs m-9,737-8,844 110.1%  
From Financial Activity Rs m5155,026 10.2%  
Net Cashflow Rs m-29-693 4.2%  

Share Holding

Indian Promoters % 74.8 74.1 100.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 2.9 286.2%  
FIIs % 5.9 9.1 64.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 13.9 79.1%  
Shareholders   44,069 49,328 89.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   WYETH LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  SUN PHARMA  PFIZER  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Up 274.4% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (up 274.4% YoY). Sales on the other hand came in at Rs 29 bn (up 29.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Sep 21, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS